NLAB Saga® is a perfectly spherical, fully porous silica with superior mechanical stability and exceptional chemical stability at high and low pH, making it an optimum choice for large scale purification of peptides.
NLAB Saga® particles in a scanning electron microscope
Nanologica offers a range of high-class chromatography resins. Due to excellent separation qualities and long lifetimes for the products,
they can streamline purification workflows and lower manufacturing costs for pharmaceutical manufacturers.
Lower costs. Higher productivity. Long lifetime.
Interview with Katarina Alenäs,
SVP Chromatography
Interview with Olga Krivosheeva, Ph.D.
Application Project Manager
Interview with Chunfang Zhou, Ph.D.
Sales Manager China
NLAB Saga® is sold in bulk. Please contact sales@nanologica.com for more information and orders.
| Product | Pore size | Particle size | Phase | Article no. |
|---|---|---|---|---|
| NLAB Saga 100-10-SIL | 100 Å | 10 µm | SIL | S700I1 |
| NLAB Saga 100-10-C4 | 100 Å | 10 µm | C4 | C700S1 |
| NLAB Saga 100-10-C8 | 100 Å | 10 µm | C8 | B700S1 |
| NLAB Saga 100-10-C18 | 100 Å | 10 µm | C18 | A700S1 |
| NLAB Saga 100-13-SIL | 100 Å | 13 µm | SIL | S800I1 |
| NLAB Saga 100-13-C8 | 100 Å | 13 µm | C8 | B800S1 |
| NLAB Saga 100-5-SIL | 100 Å | 5 µm | SIL | S500I1 |
| NLAB Saga 100-3.5-SIL | 100 Å | 3.5 µm | SIL | S300I1 |
In accordance with the current nomination committee instructions, the chairman of the board has contacted Nanologica’s three largest shareholders or owner groups in terms of
On October 23, 2026, Nanologica AB (publ) announced that Mark Quick has been appointed as the new CEO, provided that the Swedish Companies Registration Office
Incoming CEO Mark Quick and outgoing CEO Andreas Bhagwani talks about the Nanologica Group and the upcoming rights issue.
Mark Quick on taking over as the CEO of the Nanologica Group.
The Nanologica Group in short.
More about the Nanologica Group.
About the upcoming rights issue.
Nanologica is a Swedish life science group that offers advanced solutions in the development, manufacture and purification of pharmaceutical substances. By combining expertise in materials science, nanotechnology, and chemical process development, with services in contract development and manufacturing, Nanologica provides an integrated platform that supports the entire value chain from early development to commercial production of pharmaceutical substances.
Nanologica AB (publ) develops, manufactures, and sells advanced chromatography media to pharmaceutical manufacturers. Nanologica’s products are specially developed for the purification of peptide drugs, such as insulin and GLP-1 analogues. Due to effective purification and a long lifetime for the products, they can increase productivity and reduce costs for pharmaceutical manufacturers. Nanologica operates in a global niche market that is growing as a result of increased demand for drugs for the treatment of diabetes and obesity.
The Group also includes Syntagon, a contract manufacturer of drug molecules for both clinical studies and commercial delivery. Syntagon works with chemical engineering manufacturing and the development of processes and analyses of pharmaceutical raw materials, with a core competence in small molecules and peptides, and a particular strength in purification and analysis of complex compounds.
Nanologica is headquartered in Södertälje and Nanologica’s share (NICA) is listed for trading on Nasdaq Stockholm Main Market.
Nanologica is a public company listed for trade on Nasdaq Stockholm Main Market under the ticker NICA. For information regarding financial reports, press releases, presentations and share holder information, please visit our investor relations section.
